The Iceland Tribune
SEE OTHER BRANDS

Your daily news update on Iceland

Press Releases

Looking for more press releases? Explore our full press release archive by date to access past announcements, news updates, and media releases published on The Iceland Tribune.

Six Weeks Until the Scandinavian & Nordic Gaming Show 2025 – Chairperson Shares Key Market Developments
Company name change to Amaroq Ltd.
Profusa Adopts NVIDIA-Powered Technology to Build AI-Driven Insight Portal for Continuous Biomarker Monitoring
Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee in Switzerland
Content Management is Dead — Contentstack Announces Agent OS to Power Adaptive Experiences in the “Context Economy”
Closing of Fundraising and Admission
Business aviation leader Luxaviation and Haffner Energy double down on partnership with new SAF offtake agreement
The Hidden Vegetables Cookbook Offers a New Approach to Healthy Eating Without the Stigma
Notice of Results and Investor Presentation
MEDIA ADVISORY: Carbon Capture Canada: Major Events
EU Reports 23 Percent Decline in Asylum Applications
EU Asylum Applications Drop Sharply
Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT
Commencement of Trading on OTCQX in the U.S.
Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol)
'Let’s Walk' with Halli: A Podcast Designed to Spark Creativity—One Conversation at a Time
Alvotech’s Lenders Lower Interest on Senior Secured Term Loan Facility
Main Results of 2025 Annual and Extraordinary General Meeting
Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)
European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions